Wednesday, June 3, 2020

Lupin inks distribution pact with 3 firms to commercialise NaMuscla in Europe

Lupin inks distribution pact with 3 firms to commercialise NaMuscla in Europe Exeltis Healthcare SL, Cresco Pharma BV and Macure Pharma ApS will commercialise NaMuscla for the symptomatic treatment of myotonia in adults with non-dystrophic myotonic (NDM) disorders in certain European Union (EU) territories, Lupin said in a statement.

from Moneycontrol Business News https://ift.tt/3eCIAUW
Labels:

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)

D-St surges 1% on reports govt to cut tax on foreign bond bets

Indian stock markets surged on Thursday. The Nifty and Sensex saw significant gains. This rise was driven by reports of a potential tax cut ...